v3.22.2.2
Collaboration Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2022
Jan. 31, 2021
Dec. 31, 2019
Jun. 30, 2019
Aug. 31, 2022
Aug. 31, 2021
Aug. 31, 2022
Aug. 31, 2021
Nov. 30, 2022
Nov. 30, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Collaboration revenue         $ 10,791,000 $ 10,252,000 $ 31,844,000 $ 22,354,000    
Deferred revenue, current         36,342,000   36,342,000     $ 41,212,000
Gilead Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment       $ 45,000,000.0            
Upfront payment of additional fees       3,000,000.0            
Research milestones payments received             32,000,000.0      
Variable consideration included in transaction price       $ 34,500,000 2,500,000   $ 2,500,000      
Collaboration agreement contract term             5 years      
Collaboration revenue         7,200,000 6,100,000 $ 19,500,000 12,500,000    
Collaboration revenue recognized from opening contract liability         5,600,000 4,000,000.0 14,300,000 9,600,000    
Performance obligation satisfied         600,000 1,200,000 4,100,000 1,900,000    
Recorded deferred revenue         29,100,000   29,100,000     41,100,000
Deferred revenue, current         15,900,000   15,900,000     19,900,000
Accounts receivable                   6,000,000.0
Contract asset unbilled amount         2,500,000   2,500,000      
Gilead Agreement | Forecast                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Recognized research milestone payments to be received                 $ 2,500,000  
Gilead Agreement | Maximum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment of additional fees receivable         2,300,000,000   2,300,000,000      
Sanofi Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment   $ 55,000,000.0 $ 55,000,000.0              
Research milestones payments received             3,000.0      
Variable consideration included in transaction price   3,000,000.0                
Collaboration revenue recognized from opening contract liability         3,600,000 4,000,000.0 11,800,000 9,600,000    
Performance obligation satisfied         0   400,000      
Recorded deferred revenue         48,800,000   48,800,000     59,200,000
Deferred revenue, current         20,500,000   $ 20,500,000     $ 21,300,000
Additional payment received to exercise option to expand number of targets   $ 22,000,000.0                
Contractual initial research period 5 years 3 months           4 years 3 months      
Collaboration revenue         3,600,000 $ 4,200,000 $ 12,400,000 $ 9,800,000    
Sanofi Agreement | Maximum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Extended research term 5 years 3 months                  
Milestone payments additional fees receivable         $ 2,500   $ 2,500      
Sanofi Agreement | Minimum [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Extended research term 1 year